Zyvox Dosage/Direction for Use

Patients whose therapy is started with linezolid injection may be switched to linezolid tablets, with no dosage adjustment. (See Table 2.)

Click on icon to see table/diagram/image

Elderly patients: No dose adjustment is required.
Patients with renal insufficiency: No dose adjustment is required (see Pharmacology: Pharmacokinetics under Actions).
Patients with severe renal insufficiency (i.e., CL_CR <30 mL/min): No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10 fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk.
As approximately 30% of a linezolid dose is removed during 3 hours of hemodialysis, linezolid should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by hemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.
Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis and only when the anticipated benefit is considered to outweigh the theoretical risk.
To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than hemodialysis).
Patients with hepatic insufficiency: No dose adjustment is required. However, there are limited clinical data and it is recommended that linezolid should be used in such patients only when the anticipated benefit is considered to outweigh the theoretical risk (see Pharmacology: Pharmacokinetics under Actions).
Linezolid Solution for infusion: Administer linezolid solution for infusion by intravenous infusion over a period of 30 to 120 minutes. Do not use this intravenous infusion bag in series connections. Do not introduce additives into the intravenous solution. If linezolid solution for infusion is to be given concomitantly with another drug, each drug should be given separately, in accordance with the recommended dosage and route of administration for each product.
Linezolid solution for infusion was physically incompatible with the following drugs when combined in simulated Y-site administration: amphotericin B, chlorpromazine HCl, diazepam, pentamidine isethionate, phenytoin sodium, erythromycin lactobionate, and trimethoprim-sulfamethoxazole.
Linezolid solution for infusion was chemically incompatible when combined with ceftriaxone sodium.
Compatible Intravenous Solutions: 5% Dextrose Injection, USP; 0.9% Sodium Chloride Injection, USP; Lactated Ringer's Injection, USP.